Prospera Private Wealth LLC Buys 602 Shares of Sanofi (NASDAQ:SNY)

Prospera Private Wealth LLC grew its position in Sanofi (NASDAQ:SNY) by 3.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,467 shares of the company’s stock after buying an additional 602 shares during the period. Prospera Private Wealth LLC’s holdings in Sanofi were worth $1,064,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Northwest Investment Counselors LLC purchased a new stake in Sanofi in the third quarter valued at about $29,000. POM Investment Strategies LLC acquired a new stake in Sanofi in the 2nd quarter worth approximately $25,000. Concord Wealth Partners grew its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the last quarter. Arrow Financial Corp acquired a new position in Sanofi during the 2nd quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC raised its holdings in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Trading Down 1.1 %

Sanofi stock opened at $48.00 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market cap of $121.82 billion, a PE ratio of 24.49, a P/E/G ratio of 1.22 and a beta of 0.61. The stock’s 50 day simple moving average is $54.25 and its two-hundred day simple moving average is $52.22. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.55 earnings per share. Analysts anticipate that Sanofi will post 4.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SNY shares. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.